Beijing Science Sun Pharmaceutical Co., Ltd. (SHE:300485)
China flag China · Delayed Price · Currency is CNY
7.44
-0.26 (-3.38%)
Nov 13, 2026, 3:04 PM CST

SHE:300485 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
352.17398.32414.95475.92733.731,050
Other Revenue
6.46.41.530.650.821.15
358.57404.72416.48476.57734.551,051
Revenue Growth
-10.85%-2.82%-12.61%-35.12%-30.10%-3.97%
Cost of Revenue
130.53147.59143.23140.94171.61182.12
Gross Profit
228.03257.13273.26335.63562.94868.68
Selling, General & Admin
188.37197.43199.12292.63429.92658.62
Research & Development
64.5769.5146.2277.73100.63103.84
Other Operating Expenses
8.618.336.656.618.7611.74
Operating Expenses
259.99274.38250.81375.38538.7773.27
Operating Income
-31.96-17.2522.44-39.7524.2495.41
Interest Expense
-0.45-0.45----
Interest & Investment Income
9.3429.551.7160.9187.19144.34
Currency Exchange Gain (Loss)
0.350.3500-0-0
Other Non Operating Income (Expenses)
4.21-0.030.25-0.05-0.33-0.26
EBT Excluding Unusual Items
-18.5112.1824.421.11111.1239.49
Gain (Loss) on Sale of Investments
-187.168.61-108.13100.27125.41185.65
Gain (Loss) on Sale of Assets
-0.11-06.656.57
Asset Writedown
-0.01-11.38---0.04-0
Other Unusual Items
3.042.750.10.7411.437.2
Pretax Income
-202.6112.3-83.57122.16254.62439.02
Income Tax Expense
-29.384.51-6.6925.7651.9743.89
Earnings From Continuing Operations
-173.237.79-76.8796.41202.65395.13
Minority Interest in Earnings
6.496.788.026.512.097.14
Net Income
-166.7314.57-68.85102.92204.73402.27
Net Income to Common
-166.7314.57-68.85102.92204.73402.27
Net Income Growth
----49.73%-49.10%159.69%
Shares Outstanding (Basic)
492486492490476479
Shares Outstanding (Diluted)
492486492490476479
Shares Change
3.05%-1.24%0.35%2.93%-0.58%-1.07%
EPS (Basic)
-0.340.03-0.140.210.430.84
EPS (Diluted)
-0.340.03-0.140.210.430.84
EPS Growth
----51.16%-48.81%162.50%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-73.41-73.234.85-31.767.15137.38
Free Cash Flow Per Share
-0.15-0.150.07-0.070.140.29
Dividend Per Share
0.3000.300-0.0220.0860.168
Dividend Growth
----74.42%-48.81%158.46%
Gross Margin
63.59%63.53%65.61%70.43%76.64%82.67%
Operating Margin
-8.91%-4.26%5.39%-8.34%3.30%9.08%
Profit Margin
-46.50%3.60%-16.53%21.60%27.87%38.28%
Free Cash Flow Margin
-20.47%-18.09%8.37%-6.65%9.14%13.07%
EBITDA
14.9429.6669.348.6471.64151.09
EBITDA Margin
4.17%7.33%16.65%1.81%9.75%14.38%
D&A For EBITDA
46.946.946.948.3947.3955.68
EBIT
-31.96-17.2522.44-39.7524.2495.41
EBIT Margin
-8.91%-4.26%5.39%-8.34%3.30%9.08%
Effective Tax Rate
-36.69%-21.08%20.41%10.00%
Revenue as Reported
96.09404.72416.48476.57734.551,051
Advertising Expenses
---2.4137.51293.09